The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Open accessAbstract
Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable efficacy of ICIs, oncologists endeavor to explore the mechanisms of resistance to ICIs and increase the drug sensitivity. It is known that heterogeneity of gut microbiome in populations may result in different outcomes of therapy. In xenograft model, bacteria in gut have been proved as a crucial factor regulating immunotherapy efficacy. And the similar phenomenon was obtained in patients. In this review, we summarized relevant advancements about gut microbiome and ICIs. Furthermore, we focused on modulatory function of gut microbiome in ICIs therapy and possible antitumor mechanism of specific commensals in ICIs treatment. We propose that gut microbiome is an important predictive factor, and manipulation of gut microbiome is feasible to elevate response rate in ICIs therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some gut bacteria act as suppressors of inhibitory signal pathways, facilitate antigen presentation, and improve specific antitumor immunity (118).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [118]
In the citing paper
“In conclusion, in view of the metabolic function elicited by gut microbiota, we infer that their metabolic byproducts are perceived by cells and molecules of the immune system and modulate the equilibrium between pro- and antitumor functions.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [118]
In the citing paper
“The influence of gut microbiota on host immunity is multifaceted, simultaneously regulating the gut mucosal immune system and systemic immune system (Fig. 2d) [307–310].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [308]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 15×
“The fecal microbiome transplantation in mice supported the conclusions aforementioned [11].”
BackgroundMethodResultInfluential
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Self-citationNovel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
Self-citationBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Self-citationRegulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Self-citationRNA sequencing: new technologies and applications in cancer research
Hong, M., Tao, S., Zhang, L., Diao, L., Huang, X., Huang, S., Xie, S., Xiao, Z., & Zhang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01005-x · Cited by 626
Targeting the IDO1 pathway in cancer: from bench to bedside
Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 456
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
Self-citationNext generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Yu, S., Yi, M., Qin, S., & Wu, K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1057-4 · Cited by 269
Self-citationLee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004779 · Cited by 217
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin, R., Netti, G. S., Spadaccino, F., Porta, C., Gesualdo, L., Stallone, G., Castellano, G., & Ranieri, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574271 · Cited by 208
Akkermansia muciniphila and Faecalibacterium prausnitzii in Immune-Related Diseases
Effendi, R. M. R. A., Anshory, M., Kalim, H., Dwiyana, R. F., Suwarsa, O., Pardo, L. M., Nijsten, T. E. C., & Thio, H. B. (2022) · Microorganisms · doi:10.3390/microorganisms10122382 · Cited by 193
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153
Self-citationHu, Y., Li, J., Ni, F., Yang, Z., Gui, X., Bao, Z., Zhao, H., Wei, G., Wang, Y., Zhang, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32960-3 · Cited by 155
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Wei, J., Liu, Y., Wang, C., Zhang, Y., Tong, C., Dai, G., Wang, W., Rasko, J. E. J., Melenhorst, J. J., Qian, W., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00256-x · Cited by 146
Shi, L., Sheng, J., Chen, G., Zhu, P., Shi, C., Li, B., Park, C., Wang, J., Zhang, B., Liu, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000973 · Cited by 133
The role of neoantigen in immune checkpoint blockade therapy
Yi, M., Qin, S., Zhao, W., Yu, S., Chu, Q., & Wu, K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0120-y · Cited by 132
Self-citationPredictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Niu, M., Yi, M., Li, N., Luo, S., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00211-8 · Cited by 129
Self-citationAdvances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117
Self-citationGut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
Gong, J., Chehrazi‐Raffle, A., Placencio-Hickok, V., Guan, M., Hendifar, A. E., & Salgia, R. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0225-x · Cited by 112
Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
Szczyrek, M., Bitkowska, P., Chunowski, P., Czuchryta, P., Krawczyk, P. A., & Milanowski, J. (2021) · Nutrients · doi:10.3390/nu13072217 · Cited by 104
Unexpected therapeutic effects of cisplatin
Raudenská, M., Balvan, J., Fojtů, M., Gumulec, J., & Masařík, M. (2019) · Metallomics · doi:10.1039/c9mt00049f · Cited by 109
Wang, N.-H., Lei, Z., Yang, H.-N., Tang, Z., Yang, M., Wang, Y., Sui, J.-D., & Wu, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6049 · Cited by 106
Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
Verdura, S., Cuyàs, E., Martı́n-Castillo, B., & Menéndez, J. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1633235 · Cited by 99
Intestinal microbiota: a new force in cancer immunotherapy
Dai, Z., Zhang, J., Wu, Q., Fang, H., Shi, C., Li, Z., Lin, C., Tang, D., & Wang, D. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00599-6 · Cited by 98
The Gut Microbiome and Female Health
Siddiqui, R., Makhlouf, Z., Alharbi, A. M., Alfahemi, H. H., & Khan, N. A. (2022) · Biology · doi:10.3390/biology11111683 · Cited by 111
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96
Self-citationTGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 95
Self-citationThe Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy
Aarnoutse, R., Ziemons, J., Penders, J., Rensen, S. S., de Vos‐Geelen, J., & Smidt, M. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174145 · Cited by 84
Intratumor microbiome in cancer progression: current developments, challenges and future trends
Liu, J., & Zhang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00381-5 · Cited by 83
Liu, J., Chen, C., Wang, Y., Qian, C., Wei, J., Xing, Y., & Bai, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.746647 · Cited by 77
Ponziani, F. R., De Luca, A., Picca, A., Marzetti, E., Petito, V., Del Chierico, F., Reddel, S., Paroni Sterbini, F., Sanguinetti, M., Putignani, L., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1905 · Cited by 77
Lu, L., Dong, J., Liu, Y., Qian, Y., Zhang, G., Zhou, W., Zhao, A., Ji, G., & Xu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964793 · Cited by 73
Self-citationManipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69
Self-citationLiu, W., Ma, F., Sun, B., Liu, Y., Tang, H., Luo, J., Chen, H., & Luo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.756872 · Cited by 70
Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy
Zhang, X., Liu, Q., Liao, Q., & Zhao, Y. (2020) · Journal of Cancer · doi:10.7150/jca.37445 · Cited by 68
Self-citationInamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.006 · Cited by 63
Dóra, D., Ligeti, B., Kovács, T., Revisnyei, P., Gálffy, G., Dulka, E., Krizsán, D., Kalcsevszki, R., Megyesfalvi, Z., Döme, B., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2204746 · Cited by 63
Dutta, D., & Lim, S. H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00211-6 · Cited by 61
Roles of microbiota in response to cancer immunotherapy
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.026 · Cited by 62
Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
Wang, L., Ma, Q., Yao, R., & Liu, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106088 · Cited by 60
Dinh, N. T. M., Nguyen, T. M., Park, M. K., & Lee, C. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020717 · Cited by 60
Integrating the Tumor Microenvironment into Cancer Therapy
Sanegre, S., Lucantoni, F., Burgos-Panadero, R., de la Cruz-Merino, L., Noguera, R., & Naranjo, T. Á. (2020) · Cancers · doi:10.3390/cancers12061677 · Cited by 49
Huang, C.-L., Li, M., Liu, B., Zhu, H., Dai, Q., Fan, X., Mehta, K. D., Huang, C. H., Neupane, P. C., Wang, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642110 · Cited by 60
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 60
Aziz, R. K., Hegazy, S. M., Yasser, R., Rizkallah, M. R., & ElRakaiby, M. T. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530216 · Cited by 55
Han, L., Zhang, H., Chen, S., Zhou, L., Li, Y., Zhao, K., Huang, F., Fan, Z., Xuan, L., Zhang, X., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.07.006 · Cited by 53
Self-citationGut microbiome and CAR-T therapy
Abid, M. B., Shah, N. N., Maatman, T. C., & Hari, P. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0155-8 · Cited by 57
Intratumoral bacteria are an important “accomplice” in tumor development and metastasis
Wang, G., He, X., & Wang, Q. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188846 · Cited by 51
Autism spectrum disorder is associated with gut microbiota disorder in children
Sun, H., You, Z., Jia, L., & Wang, F. (2019) · BMC Pediatrics · doi:10.1186/s12887-019-1896-6 · Cited by 53
Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light
Zhang, J., Wu, K.-H., Shi, C., & Li, G. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01027-2 · Cited by 50
Self-citationSun, Y., Yang, Q., Shen, J., Wei, T., Shen, W., Zhang, N., Luo, P., & Zhang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.745859 · Cited by 48
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
Yang, B., Liu, T., Qu, Y., Liu, H., Zheng, S. G., Cheng, B., & Sun, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00563 · Cited by 47
Kang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 46
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 52
Self-citationImmunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49
Entezam, M., Sanaei, M., Mirzaei, Y., Mer, A. H., Abdollahpour‐Alitappeh, M., Azadegan‐Dehkordi, F., & Bagheri, N. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121459 · Cited by 44
Long, L. L., Svenson, K. L., Mourino, A. J., Michaud, M., Fahey, J. R., Waterman, L., Vandegrift, K. L., & Adams, M. D. (2021) · Lab Animal · doi:10.1038/s41684-021-00777-0 · Cited by 44
Kim, J. H., Ahn, B., Hong, S., Jung, H., Kim, D. H., Choi, K. D., Ahn, J. Y., Lee, J. H., Na, H. K., Kim, J. H., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2020.1198 · Cited by 42
Stamm, H., Wellbrock, J., & Fiedler, W. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9770-7 · Cited by 41
Miglietta, F., Griguolo, G., Guarneri, V., & Dieci, M. V. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0197 · Cited by 39
Understanding asthma and allergies by the lens of biodiversity and epigenetic changes
Fiuza, B. S. D., Fonseca, H. F., Meirelles, P. M., Marques, C. R., da Silva, T. M., & Figueiredo, C. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623737 · Cited by 38
Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
Rodallec, A., Sicard, G., Fanciullino, R., Benzekry, S., Lacarelle, B., Milano, G. A., & Ciccolini, J. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1540588 · Cited by 39
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Jantz-Naeem, N., Loschinski, R., Borucki, K., Mitchell-Flack, M., Böttcher, M., Schraven, B. L., Mougiakakos, D., & Kahlfuß, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1060112 · Cited by 37
Gut bacteria formation and influencing factors
Yang, J., Wu, J., Li, Y., Zhang, Y., Cho, W. C. S., Ju, X., van Schothorst, E. M., & Zheng, Y. (2021) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiab043 · Cited by 36
Xu, H., Xu, X., Wang, H., Ge, W., & Cao, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102909 · Cited by 33
Self-citationTyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome
Li, X., Lin, Y., Li, X., Xu, X., Zhao, Y., Xu, L., Gao, Y., Li, Y., Tan, Y., Qian, P., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103048 · Cited by 34
The role of gut microbiota in immune checkpoint inhibitor therapy
Yi, M., Qin, S., Chu, Q., & Wu, K. (2018) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.11.12 · Cited by 32
Self-citationSphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis
Lau, P., Zhang, G., Zhao, S., Liang, L., Zhang, H., Zhou, G., Hung, M., Chen, X., & Liu, H. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00911-z · Cited by 30
Race, the microbiome and colorectal cancer
Royston, K. J., Adedokun, B., & Olopade, O. I. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.773 · Cited by 30
Lu, P., Tsai, T., Chang, J. W., Deng, S., & Cheng, C. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13298 · Cited by 30
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 29
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma
Yavuz, B. G., Datar, S. S., Chamseddine, S., Mohamed, Y. I., LaPelusa, M. B., Lee, S. S., Hu, Z. I., Koay, E. J., Cao, H. S. T., Jalal, P. K., et al. (2023) · Cancers · doi:10.3390/cancers15194875 · Cited by 30
Brown, S.-A. N., Ray, J. C., & Herrmann, J. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09992-5 · Cited by 29
Microbiome as a Target for Cancer Therapy
Suraya, R., Nagano, T., Kobayashi, K., & Nishimura, Y. (2020) · Integrative Cancer Therapies · doi:10.1177/1534735420920721 · Cited by 27
Inchingolo, A. M., Malcangi, G., Piras, F., Palmieri, G., Settanni, V., Riccaldo, L., Morolla, R., Buongiorno, S., de Ruvo, E., Inchingolo, A. D., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060933 · Cited by 30
RetractedMetformin as a booster of cancer immunotherapy
Panaampon, J., Zhou, Y., & Saengboonmee, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110528 · Cited by 28
The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors
Alkharabsheh, O. A., Sidiqi, M. H., Aljama, M. A., Gertz, M. A., & Frankel, A. E. (2019) · Acta Haematologica · doi:10.1159/000500976 · Cited by 27
Borgers, J. S. W., Burgers, F. H., Terveer, E. M., van Leerdam, M. E., Korse, C. M., Kessels, R., Flohil, C. C., Blank, C. U., Schumacher, T. N., van Dijk, M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10457-y · Cited by 29
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martín-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 26
Gut microbiota-mediated tributyltin-induced metabolic disorder in rats
Yuan, G., Zhang, Z., Gao, X., Zhu, J., Guo, W., Wang, L., Ding, P., Jiang, P., & Li, L. (2020) · RSC Advances · doi:10.1039/d0ra07502g · Cited by 25
PD ‐1/ PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
Hosseinzadeh, R., Feizisani, F., Shomali, N., Abdelbasset, W. K., Hemmatzadeh, M., Navashenaq, J. G., Jadidi‐Niaragh, F., Bokov, D. O., Janebifam, M., & Mohammadi, H. (2021) · IUBMB Life · doi:10.1002/iub.2558 · Cited by 25
Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
Zhou, Y., Liu, Z., & Chen, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847350 · Cited by 25
Immune Checkpoints in Endometriosis—A New Insight in the Pathogenesis
Suszczyk, D., Skiba, W., Pawłowska, A., Dymanowska-Dyjak, I., Włodarczyk, K., Paduch, R., & Wertel, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116266 · Cited by 26
Anticancer natural products targeting immune checkpoint protein network
Chun, K., Kim, D., Raut, P. K., & Surh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.006 · Cited by 24
Frąk, M., Grenda, A., Krawczyk, P. A., Milanowski, J., & Kalinka‐Warzocha, E. (2022) · Cancers · doi:10.3390/cancers14225577 · Cited by 25
Geum, M. J., Kim, C., Kang, J. E., Choi, J. H., Kim, J. S., Son, E. S., Lim, S. M., & Rhie, S. J. (2021) · Pharmaceuticals · doi:10.3390/ph14050445 · Cited by 22
Microbiome modulation of tumorigenesis and immune responses
Chen, Y., Fang, Y., Lyu, Z., Tian, Y., Niu, S., Li, Y.-R., & Yang, L. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01208-9 · Cited by 28
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21
Tomela, K., Pietrzak, B., SCHMIDT, M. T., & Mackiewicz, A. A. (2020) · Life · doi:10.3390/life10100219 · Cited by 21
MDM2 inhibitors in cancer immunotherapy: Current status and perspective
Zeng, Q., Zeng, S., Dai, X., Ding, Y., Huang, C., Ruan, R., Xiong, J., Tang, X., & Deng, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101279 · Cited by 20
Zapata, M. E. S., Pellitero, A. M., Isla, D., Gálvez, E. H., Ruiz, M. G., Sesma, A., Barbero-Herranz, R., Galeano, J., del Campo, R., Ocáriz, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33684 · Cited by 20
Alshammari, K. M., Alotaibi, F., Alsugheir, F., Aldawoud, M., Alolayan, A. A. M., Algarni, M., Sabatin, F., Mohammad, M. F., Alosaimi, A., Sanai, F. M., et al. (2023) · Cancers · doi:10.3390/cancers16010133 · Cited by 19
Sun, L., Wang, X., Zhou, H., Li, R., Meng, M., Roviello, G., Oh, B., Feng, L., Yu, Z., & Wang, J. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-1201 · Cited by 20
Zhou, H. P., Chen, Y., Yu, X., Wu, Q., Li, H., Li, Y., Su, G., Ke, L., Wu, J., & Li, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050721 · Cited by 18
Wang, L. (2021) · Current Research in Translational Medicine · doi:10.1016/j.retram.2021.103320 · Cited by 17
Metadata
- Authors
- Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K.
- Affiliations
- Tongji Hospital (CN)
- Corresponding author
- Chu, Qian
- Wu, Kongming
- Venue
- Journal of Hematology & Oncology
- Published
- 2018-03-27
- Volume
- 11
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC5870075
- OpenAlex
- W2794616539
- Cited by
- 179
- References
- 110
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 17 · 2023: 23 · 2022: 32 · 2021: 26 · 2020: 24 · 2019: 26 · 2018: 10
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81572608 and 81172422, 81672984)
- Wuhan Science and Technology Bureau (2017060201010170)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, immune checkpoint inhibitors, immunotherapy efficacy, cancer immunotherapy, treatment resistance, predictive biomarkers, commensal bacteria, anticancer mechanism, microbiome manipulation
- MeSH terms
- Gastrointestinal Microbiome, Humans, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
